Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

被引：3

作者：

Bhurani, Mansi ^{[1
,2
,3
]}

Admojo, Lorenz ^{[1
,2
]}

Van der Weyden, Carrie ^{[1
,2
]}

Twigger, Robert ^{[1
,2
]}

Bazargan, Ali ^{[4
]}

Quach, Hang ^{[4
]}

Zimet, Allan ^{[5
]}

Coyle, Luke ^{[6
]}

Lindsay, Julian ^{[6
]}

Radeski, Dejan ^{[7
]}

Hawkes, Eliza ^{[8
]}

Kennedy, Glen ^{[9
]}

Irving, Ian ^{[10
]}

Gutta, Naadir ^{[10
]}

Trotman, Judith ^{[11
]}

Yeung, James ^{[11
,12
]}

Dunlop, Lindsay ^{[13
]}

Hua, Minh ^{[12
]}

Giri, Pratyush ^{[14
]}

Yuen, Sam ^{[15
]}

Panicker, Shyam ^{[16
]}

Moreton, Susan ^{[17
]}

Khoo, Liane ^{[12
]}

Scott, Ashleigh ^{[18
,19
]}

Kipp, David ^{[20
]}

McQuillan, Andrew ^{[21
]}

McCormack, Chris ^{[1
,19
]}

Dickinson, Michael ^{[1
,2
]}

Prince, Henry Miles ^{[1
,2
,3
,5
]}

机构：

[1] Peter MacCallum Canc Ctr, Div Canc Med, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia

[3] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia

[4] St Vincents Hlth, Melbourne, Vic, Australia

[5] Epworth Healthcare, Melbourne, Vic, Australia

[6] Royal North Shore Hosp, Sydney, NSW, Australia

[7] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[8] Austin Hlth, Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia

[9] Mater Canc Care Ctr, Brisbane, Qld, Australia

[10] Icon Canc Care, Brisbane, Qld, Australia

[11] Concord Hosp, Sydney, NSW, Australia

[12] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[13] Southern Highland Private Hosp, Liverpool, NSW, Australia

[14] Royal Adelaide Hosp, Adelaide, SA, Australia

[15] Calvary Mater, Newcastle, NSW, Australia

[16] Hills Specialist Grp, Bella Vista, NSW, Australia

[17] Dubbo Base Hosp, Dubbo, NSW, Australia

[18] Royal Brisbane & Womens Hosp, Herston, Qld, Australia

[19] Sir Peter MacCallum Dept Surg Oncol, Parkville, Vic, Australia

[20] Barwon Hlth Canc Serv, Geelong, Vic, Australia

[21] Hollywood Med Ctr, Nedlands, WA, Australia

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Pralatrexate; T-cell lymphoma; peripheral T-cell lymphoma; cutaneous T-cell lymphoma; mucositis; ETOPOSIDE;

D O I：

10.1080/10428194.2020.1827241

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treatedviaa compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median OS was 10 months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. Mucositis was the most commonly observed toxicity. This study - the second largest real-world cohort reported to date - underscores the importance of pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable toxicity profile.

引用

页码：330 / 336

页数：7

共 23 条

[1]

AbouYabis A, 2011, ISRN HEMATOL, V2011

[2] The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project [J].

Bellei, Monica ;

Nabhan, Chadi ;

Pesce, Emanuela Anna ;

Conte, Luana ;

Vose, Julie M. ;

Foss, Francine ;

Federico, Massimo .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2015, 10 (04) :448-455

[3] Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial [J].

Budde, Lihua E. ;

Shustov, Andrei ;

Pagel, John M. ;

Gooley, Ted ;

Oliyiera, George ;

Chen, Tara ;

Zhang, Michelle ;

Warr, Thomas A. ;

Boyd, Thomas ;

Press, Oliver W. ;

Gopal, Ajay K. .

BLOOD, 2010, 116 (21) :1150-1150

[4] Romidepsin activity in T follicular helper(TFH)-phenotype PTCL versus non TFH treated on the same clinical trials. [J].

Ghione, Paola ;

Ozkaya, Neval ;

Faruque, Promie ;

Mehta-Shah, Neha ;

Lunning, Matthew Alexander ;

Ruan, Jia ;

Galasso, Natasha ;

Moskowitz, Alison J. ;

Dogan, Ahmet ;

Horwitz, Steven M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[5] Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial [J].

Horwitz, Steven ;

O'Connor, Owen A. ;

Pro, Barbara ;

Illidge, Tim ;

Fanale, Michelle ;

Advani, Ranjana ;

Bartlett, Nancy L. ;

Christensen, Jacob Haaber ;

Morschhauser, Franck ;

Domingo-Domenech, Eva ;

Rossi, Giuseppe ;

Kim, Won Seog ;

Feldman, Tatyana ;

Lennard, Anne ;

Belada, David ;

Illes, Arpad ;

Tobinai, Kensei ;

Tsukasaki, Kunihiro ;

Yeh, Su-Peng ;

Shustov, Andrei ;

Huttmann, Andreas ;

Savage, Kerry J. ;

Yuen, Sam ;

Iyer, Swaminathan ;

Zinzani, Pier Luigi ;

Hua, Zhaowei ;

Little, Meredith ;

Rao, Shangbang ;

Woolery, Joseph ;

Manley, Thomas ;

Trumper, Lorenz ;

Aboulafia, David ;

Alpdogan, Onder ;

Ando, Kiyoshi ;

Arcaini, Luca ;

Baldini, Luca ;

Bellam, Naresh ;

Bartlett, Nancy ;

Ben Yehuda, Dina ;

Benedetti, Fabio ;

Borchman, Peter ;

Bordessoule, Dominique ;

Brice, Pauline ;

Briones, Javier ;

Caballero, Dolores ;

Carella, Angelo Michele ;

Chang, Hung ;

Cheong, June Weon ;

Cho, Seok-Goo ;

Choi, Ilseung .

LANCET, 2019, 393 (10168) :229-240

[6] Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma [J].

Horwitz, Steven M. ;

Kim, Youn H. ;

Foss, Francine ;

Zain, Jasmine M. ;

Myskowski, Patricia L. ;

Lechowicz, Mary Jo ;

Fisher, David C. ;

Shustov, Andrei R. ;

Bartlett, Nancy L. ;

Delioukina, Maria L. ;

Koutsoukos, Tony ;

Saunders, Michael E. ;

O'Connor, Owen A. ;

Duvic, Madeleine .

BLOOD, 2012, 119 (18) :4115-4122

[7] Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study [J].

Kim, Youn H. ;

Whittaker, Sean ;

Horwitz, Steven M. ;

Duvic, Madeleine ;

Dummer, Reinhard ;

Scarisbrick, Julia J. ;

Quaglino, Pietro ;

Zinzani, Pier Luigi ;

Wolter, Pascal ;

Wang, Yinghui ;

Palanca-Wessels, Maria Corinna ;

Zagadailov, Erin ;

Trepicchio, William L. ;

Liu, Yi ;

Little, Meredith ;

Prince, H. Miles .

BLOOD, 2016, 128 (22)

[8] Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma [J].

Mahadevan, Daruka ;

Unger, Joseph M. ;

Spier, Catherine M. ;

Persky, Daniel O. ;

Young, Fay ;

LeBlanc, Michael ;

Fisher, Richard I. ;

Miller, Thomas P. .

CANCER, 2013, 119 (02) :371-379

[9] Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors [J].

Mak, Vivien ;

Hamm, Jeremey ;

Chhanabhai, Mukesh ;

Shenkier, Tamara ;

Klasa, Richard ;

Sehn, Laurie H. ;

Villa, Diego ;

Gascoyne, Randy D. ;

Connors, Joseph M. ;

Savage, Kerry J. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) :1970-+

[10] Folotyn (Pralatrexate Injection) for the Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: U.S. Food and Drug Administration Drug Approval Summary [J].

Malik, Shakun M. ;

Liu, Ke ;

Qiang, Xu ;

Sridhara, Rajeshwari ;

Tang, Shenghui ;

McGuinn, W. David, Jr. ;

Verbois, S. Leigh ;

Marathe, Anshu ;

Williams, Gene M. ;

Bullock, Julie ;

Tornoe, Christoffer ;

Lin, Sue Ching ;

Ocheltree, Terrance ;

Vialpando, Milinda ;

Kacuba, Alice ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2010, 16 (20) :4921-4927

← 1 2 3 →